This bill aims to continue the prohibition that prevents pharmacy benefit managers from requiring federally certified health entities to identify 340B drugs. It seeks to extend the termination date of this prohibition, ensuring that the current protections remain in place for an extended period.

Additionally, the bill amends Section 26 of Chapter 501 of the Laws of 2021, although specific details of the amendments are not provided in the summary. The bill is designed to take effect immediately upon passage, reinforcing the ongoing support for health entities participating in the 340B drug pricing program.

Statutes affected:
HB0379_1.pdf: 33-2-2410
HB0379_2.pdf: 33-2-2410
Amended: 33-2-2410
Introduced: 33-2-2410